AstraZeneca is the latest drugmaker to announce promising Phase 3 trial results from its COVID-19 vaccine candidate. On Monday, AstraZeneca said its two-shot vaccine candidate has been 90% effective ...
A handful of the dozens of experimental COVID-19 vaccines in human testing have reached the last and biggest hurdle - looking for the needed proof that they really work. AstraZeneca announced Monday ...
(Reuters) - Emergent BioSolutions Inc said on Monday it signed a $174 million agreement with AstraZeneca to develop and manufacture the British drugmaker's COVID-19 vaccine candidate. AstraZeneca in ...
Researchers identify genetic mutation in small group of people who developed the serious disorder after receiving the AstraZeneca or Johnson & Johnson vaccine. About one in 200,000 people developed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results